Ocugen

Ocugen is a dynamic biotechnology company dedicated to discovering, developing, and commercializing innovative gene and cell therapies, as well as vaccines, aimed at improving health outcomes and providing hope for patients worldwide. With a focus on courageous innovation, Ocugen is committed to forging new scientific paths that leverage its unique intellectual and human capital to make a significant impact on patient's lives.

Located at 263 Great Valley Pkwy, Malvern, Pennsylvania 19355, US, Ocugen is pioneering a breakthrough modifier gene therapy platform that holds the potential to treat multiple retinal diseases with a single product. Furthermore, Ocugen is actively advancing research in infectious diseases to support public health initiatives and orthopedic diseases to address unmet medical needs. Ocugen approaches healthcare innovation with purpose and agility to deliver new breakthroughs for people facing disease.

Ocugen continues to expand its capabilities and broaden its reach within the biotechnology sector. Information about Ocugen’s latest advancements and strategic initiatives will be completed soon with the support of the company’s management. We invite the manager of Ocugen to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.